Clinical Trial Update: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety, tolerability, and immunogenicity of VAX-31 with an influenza vaccine in adults 50 years and older; the trial is sponsored b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Influenza vaccine (influenza vaccine)
• VAX-31 (31-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Vaxcyte, Inc. | Conditions: Pneumococcal Vaccines | Phase 3 | Status: ACTIVE_NOT_RECRUITING